The FDA’s recent decision to reject MDMA-assisted therapy for market approval is undoubtedly disappointing, but not entirely surprising. This therapy, disruptive in both regulatory and clinical delivery perspectives, faced a rigorous review process, serving as a reality check for the challenges involved in approving groundbreaking drugs. Yet, this moment represents a crucial opportunity for the sector, one that will ultimately enhance research practices and advance scientific understanding.